Published in Genome Med on January 27, 2012
Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition. Oncoscience (2013) 0.94
Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. AMIA Annu Symp Proc (2014) 0.89
Label Propagation Prediction of Drug-Drug Interactions Based on Clinical Side Effects. Sci Rep (2015) 0.85
Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype data. PLoS One (2013) 0.85
Construction of drug network based on side effects and its application for drug repositioning. PLoS One (2014) 0.84
Combining automatic table classification and relationship extraction in extracting anticancer drug-side effect pairs from full-text articles. J Biomed Inform (2014) 0.84
Systematic prediction of drug combinations based on clinical side-effects. Sci Rep (2014) 0.84
PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery. J Biomed Inform (2015) 0.83
A genomics-based systems approach towards drug repositioning for rheumatoid arthritis. BMC Genomics (2016) 0.82
A chemo-centric view of human health and disease. Nat Commun (2014) 0.78
Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles. J Biomed Inform (2015) 0.78
Inferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic properties. Sci Rep (2016) 0.76
Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory. BMC Bioinformatics (2016) 0.76
Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery. BMC Genomics (2016) 0.75
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Drug target identification using side-effect similarity. Science (2008) 9.24
Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol (2010) 6.75
The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov (2011) 3.42
PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol (2011) 3.22
Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci (2010) 2.06
Systematic drug repositioning based on clinical side-effects. PLoS One (2011) 1.56
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia (2009) 1.34
Proteome survey reveals modularity of the yeast cell machinery. Nature (2006) 20.77
Potential artefacts in protein-interaction networks. FEBS Lett (2002) 2.24
3did: interacting protein domains of known three-dimensional structure. Nucleic Acids Res (2005) 2.18
Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci (2010) 2.06
A structural perspective on protein-protein interactions. Curr Opin Struct Biol (2004) 1.98
Interactome3D: adding structural details to protein networks. Nat Methods (2012) 1.89
A network medicine approach to human disease. FEBS Lett (2009) 1.83
3did: identification and classification of domain-based interactions of known three-dimensional structure. Nucleic Acids Res (2010) 1.71
3did Update: domain-domain and peptide-mediated interactions of known 3D structure. Nucleic Acids Res (2008) 1.51
Contextual specificity in peptide-mediated protein interactions. PLoS One (2008) 1.37
Structural insights into the target specificity of plant invertase and pectin methylesterase inhibitory proteins. Plant Cell (2004) 1.33
Targeting and tinkering with interaction networks. Nat Chem Biol (2008) 1.27
Ribonucleotide reductases: divergent evolution of an ancient enzyme. J Mol Evol (2002) 1.26
Pushing structural information into the yeast interactome by high-throughput protein docking experiments. PLoS Comput Biol (2009) 1.22
Three-dimensional modeling of protein interactions and complexes is going 'omics. Curr Opin Struct Biol (2011) 1.21
Towards a detailed atlas of protein-protein interactions. Curr Opin Struct Biol (2013) 1.19
3did: a catalog of domain-based interactions of known three-dimensional structure. Nucleic Acids Res (2013) 1.14
Dynamic interactions of proteins in complex networks: a more structured view. FEBS J (2009) 1.13
Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. Genome Res (2010) 1.02
Novel peptide-mediated interactions derived from high-resolution 3-dimensional structures. PLoS Comput Biol (2010) 1.02
Systematic searches for molecular synapomorphies in model metazoan genomes give some support for Ecdysozoa after accounting for the idiosyncrasies of Caenorhabditis elegans. Evol Dev (2004) 1.01
Analysis of chemical and biological features yields mechanistic insights into drug side effects. Chem Biol (2013) 1.00
Uncovering new substrates for Aurora A kinase. EMBO Rep (2010) 1.00
Approved drug mimics of short peptide ligands from protein interaction motifs. J Chem Inf Model (2008) 0.98
Towards a molecular characterisation of pathological pathways. FEBS Lett (2008) 0.96
The role of structural disorder in the rewiring of protein interactions through evolution. Mol Cell Proteomics (2012) 0.95
The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One (2013) 0.91
NetAligner--a network alignment server to compare complexes, pathways and whole interactomes. Nucleic Acids Res (2012) 0.90
Target selection for complex structural genomics. Curr Opin Struct Biol (2006) 0.90
A novel framework for the comparative analysis of biological networks. PLoS One (2012) 0.89
A second-generation protein-protein interaction network of Helicobacter pylori. Mol Cell Proteomics (2014) 0.86
Exploiting gene deletion fitness effects in yeast to understand the modular architecture of protein complexes under different growth conditions. BMC Syst Biol (2009) 0.86
A systematic study of the energetics involved in structural changes upon association and connectivity in protein interaction networks. Structure (2011) 0.83
Functional and structural analysis of C-terminal BRCA1 missense variants. PLoS One (2013) 0.82
From protein interaction networks to novel therapeutic strategies. IUBMB Life (2012) 0.82
Incorporating high-throughput proteomics experiments into structural biology pipelines: identification of the low-hanging fruits. Proteomics (2008) 0.82
Systematic bioinformatics and experimental validation of yeast complexes reduces the rate of attrition during structural investigations. Structure (2010) 0.82
Structural systems pharmacology: the role of 3D structures in next-generation drug development. Chem Biol (2013) 0.81
On the analysis of protein-protein interactions via knowledge-based potentials for the prediction of protein-protein docking. Protein Sci (2011) 0.80
A molecular interpretation of genetic interactions in yeast. FEBS Lett (2008) 0.79
Structural similarity to bridge sequence space: finding new families on the bridges. Protein Sci (2005) 0.79
Yeast mitochondrial protein-protein interactions reveal diverse complexes and disease-relevant functional relationships. J Proteome Res (2015) 0.78
Revealing the molecular relationship between type 2 diabetes and the metabolic changes induced by a very-low-carbohydrate low-fat ketogenic diet. Nutr Metab (Lond) (2010) 0.77
Predicting protein-protein interaction specificity through the integration of three-dimensional structural information and the evolutionary record of protein domains. Mol Biosyst (2010) 0.76
Discovery and hypothesis generation through bioinformatics. Genome Biol (2006) 0.75